Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Consumer Tries On Wearable Pain Relief With NeuroMetrix Deal

Executive Summary

GSK Consumer purchases ex-US rights to pain relief device Quell from NeuroMetrix in a deal that includes co-development of transcutaneous electrical nerve stimulation products.

You may also be interested in...



Supplements For Disease-Related Nutrition Shaping Consumer Health Landscape

Sales of dietary supplements promoted for nutritional needs of diabetics are exploding as consumers seek non-drug products to deal with symptoms of the disease, says a consumer health analyst in a recent presentation. Consumer health products positioned to prevent disease are growing at a much faster rate globally than those formulas that treat ailments.

UK Short-Circuits OTC Device Pain Relief Claims For Diabetics, Arthritics

Ad claims for Actegy's Revitive Circulation Booster device did not rely on clinical evidence that tested the actual product in the way consumers were advised to use it, UK advertising regulator says. Actegy maintained benefits from the device's TENS technology are similar to the effects of NMES technology used in studies it offered as evidence.

UK Short-Circuits OTC Device Pain Relief Claims For Diabetics, Arthritics

Ad claims for Actegy's Revitive Circulation Booster device did not rely on clinical evidence that tested the actual product in the way consumers were advised to use it, UK advertising regulator says. Actegy maintained benefits from the device's TENS technology are similar to the effects of NMES technology used in studies it offered as evidence.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel